SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-24-000008
Filing Date
2024-02-12
Accepted
2024-02-12 16:18:20
Documents
15
Period of Report
2024-02-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20240212.htm   iXBRL 8-K 30182
2 EX-99.1 a991_unauditedproformabala.htm EX-99.1 54762
  Complete submission text file 0001516551-24-000008.txt   206656

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20240212.xsd EX-101.SCH 1923
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20240212_lab.xml EX-101.LAB 22082
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20240212_pre.xml EX-101.PRE 11528
16 EXTRACTED XBRL INSTANCE DOCUMENT skye-20240212_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 24620188
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)